Posted by Michael Wonder on 13 Apr 2018
Rhizen Pharmaceuticals receives FDA fast track designation for tenalisib (RP6530), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed and/or refractory cutaneous T-cell lymphoma
13 April 2018 - Rhizen Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for tenalisib, the Company’s highly selective and orally active dual PI3K delta/gamma inhibitor, for the treatment of patients with relapsed and/or refractory cutaneous T-cell lymphoma.
Tenalisib (RP6530) is a highly selective and orally active dual PI3K delta/gamma inhibitor with efficient translation of activity through enzyme, cell, and whole blood-based studies.
